RCS - RUA Life Sciences - Science Journal Publication

Rua Life SciencesAnnouncement

22/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221222:nRSV5197Ka&default-theme=true

RNS Number : 5197K  RUA Life Sciences PLC  22 December 2022

22 December 2022

 

RNS REACH

 

RUA Life Sciences Plc

("RUA Life Sciences", the "Company" or the "Group")

Science Journal Publication

 

RUA Life Sciences, the holding company of a group of medical device businesses
focused on the exploitation of the patented long-term implantable biostable
polymer, Elast-EonTM, is pleased to announce that further to a presentation at
EACTS in 2021 a detailed paper  has now been accepted for publication in the
Journal of Surgical Research discussing the RUA large bore graft and its
similar safety and performance to the control devices. The paper, titled "A
Large-Diameter Vascular Graft Replacing Animal-Derived Sealants with an
Elastomeric Polymer", can be read on Science Direct by following the link
below:

www.sciencedirect.com/science/article/pii/S002248042200782X
(http://www.sciencedirect.com/science/article/pii/S002248042200782X)

A copy of the paper will also be available on the RUA Life Sciences website.

Bill Brown, Chairman of RUA Life Sciences quoted:

"I would like to thank the team at Leuven for the preparation of this paper.
No surprises came out of the study and I am delighted that the RUA graft
behaved well in surgical handling and overall outcome with the ElastEon
sealant performing as expected with no indications of the adhesions."

 

For more information please contact:

RUA Life Sciences

Bill Brown, Chairman
                         Tel: +44 (0)1294 317073

Dr Caroline Stretton, Group MD
            Tel: +44 (0)1294 317073

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFESFFLLFIF